404 related articles for article (PubMed ID: 26339355)
1. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
2. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
3. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
Ji WP; He NB
Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
[TBL] [Abstract][Full Text] [Related]
4. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
5. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
6. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma.
Wang MJ; Zhu Y; Guo XJ; Tian ZZ
Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406
[TBL] [Abstract][Full Text] [Related]
7. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
9. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
10. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
Zhang H; Ge J; Hong H; Bi L; Sun Z
World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.
Shi ZH; Shi GY; Liu LG
Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829
[TBL] [Abstract][Full Text] [Related]
13. Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer.
Zhao F; Shang Y; Zeng C; Gao D; Li K
Int J Clin Exp Pathol; 2015; 8(9):11579-86. PubMed ID: 26617894
[TBL] [Abstract][Full Text] [Related]
14. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.
Sun XH; Hou WG; Zhao HX; Zhao YL; Ma C; Liu Y
Asian Pac J Cancer Prev; 2013; 14(3):2049-52. PubMed ID: 23679317
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
[TBL] [Abstract][Full Text] [Related]
16. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
Gao H; Ge RC; Liu HY; Wang Y; Yan S
Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
[TBL] [Abstract][Full Text] [Related]
17. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
[TBL] [Abstract][Full Text] [Related]
18. Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.
Bai Y; Wang L; Li G; Fang X; Li Y; Yang S
Int J Clin Exp Pathol; 2015; 8(10):13367-73. PubMed ID: 26722542
[TBL] [Abstract][Full Text] [Related]
19. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
[TBL] [Abstract][Full Text] [Related]
20. Laryngeal cancer risk and common single nucleotide polymorphisms in nucleotide excision repair pathway genes ERCC1, ERCC2, ERCC3, ERCC4, ERCC5 and XPA.
Lu B; Li J; Gao Q; Yu W; Yang Q; Li X
Gene; 2014 May; 542(1):64-8. PubMed ID: 24582975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]